THEON Enters into Exclusivity Agreement for the Acquisition of HGH Systèmes Infrarouges, Accelerating Expansion into Multi-Domain ISR & Counter-UAS Solutions

Summary by AI BETAClose X

Theon International Plc has entered into an exclusivity agreement to acquire HGH Systèmes Infrarouges for an enterprise value of approximately €300 million, a move expected to significantly enhance Theon's multi-domain ISR and counter-UAS solutions. HGH, with revenues of around €40 million and an EBITDA margin exceeding 40%, boasts a strong R&D focus and an order backlog of approximately €70 million. This acquisition, anticipated to be EBITDA margin accretive and mid-single-digit EPS accretive in 2027, will be financed through a bridge facility intended for refinancing with debt, with no equity increase anticipated. The transaction, which reinforces Theon's strategic commitment to France, is expected to close by Q4 2026.

Disclaimer*

UK 100

Latest directors dealings